Business Context and Reporting Period
PolyPid Ltd., a foreign private issuer based in Petach Tikva, Israel, filed Form 6-K on December 16, 2025. The report covers corporate governance updates for the month of December 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and contains no financial performance data.
Material Changes
The primary material change reported is the appointment of Brooke Story as a director and Chairman of the Board, effective December 11, 2025. No financial or operational changes were disclosed in this document.
Guidance, Outlook, and Management Commentary
- Board Appointment: Brooke Story, age 54, brings extensive experience from BD (Becton, Dickinson and Company) and Medtronic plc. She previously served as Worldwide President of Surgery and Integrated Diagnostic Solutions at BD and President of Pelvic Health and Gastric Therapies at Medtronic.
- Independence: The Board determined Ms. Story is independent under Nasdaq Stock Market rules.
- Compensation and Agreements: Her compensation package will be proposed for shareholder approval at an upcoming meeting. The Company expects to enter into a standard indemnification agreement with her.
- Related Party Transactions: Ms. Story is not a party to any transactions disclosable under Item 7.B of Form 20-F.
Investor Verification Checklist
- Verify the shareholder approval status of Ms. Story's compensation package at the upcoming meeting.
- Confirm the execution of the standard indemnification agreement with the new Chairman.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Check subsequent filings for any financial updates, as this 6-K contains no financial data.